Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)

被引:0
作者
Hao, Wenhui [1 ]
Rajendran, Barani Kumar [2 ]
Cui, Tingting [1 ]
Sun, Jiayi [1 ]
Zhao, Yingchun [1 ]
Palaniyandi, Thirunavukkarasu [3 ]
Selvam, Masilamani [4 ]
机构
[1] Xinjiang Med Univ, Sch Basic Med Sci, Xinjiang Key Lab Mol Biol Endem Dis, 567 Shangde North Rd, Urumqi 830017, Xinjiang, Peoples R China
[2] Yale Univ, Yale Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06510 USA
[3] Dr MGR Educ & Res Inst, Dept Biotechnol, Chennai 600095, India
[4] Sathyabama Inst Sci & Technol, Dept Biotechnol, Chennai 600119, India
关键词
breast cancer; precision oncology; driver mutations; genomics; targeted therapy; cancer heterogeneity; onco-prediction; personalized medicine; immunotherapy; T-CELL RESPONSES; POXVIRAL-BASED VACCINE; METASTATIC BREAST; PHASE-II; YONDELIS(R) TRABECTEDIN; FUNCTIONAL IMPACT; EXPRESSION; HER2; IMMUNOTHERAPY; COMBINATION;
D O I
10.3892/ijmm.2024.5447
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the modern era of medicine, prognosis and treatment, options for a number of cancer types including breast cancer have been improved by the identification of cancer-specific biomarkers. The availability of high-throughput sequencing and analysis platforms, the growth of publicly available cancer databases and molecular and histological profiling facilitate the development of new drugs through a precision medicine approach. However, only a fraction of patients with breast cancer with few actionable mutations typically benefit from the precision medicine approach. In the present review, the current development in breast cancer driver gene identification, actionable breast cancer mutations, as well as the available therapeutic options, challenges and applications of breast precision oncology are systematically described. Breast cancer driver mutation-based precision oncology helps to screen key drivers involved in disease development and progression, drug sensitivity and the genes responsible for drug resistance. Advances in precision oncology will provide more targeted therapeutic options for patients with breast cancer, improving disease-free survival and potentially leading to significant successes in breast cancer treatment in the near future. Identification of driver mutations has allowed new targeted therapeutic approaches in combination with standard chemo- and immunotherapies in breast cancer. Developing new driver mutation identification strategies will help to define new therapeutic targets and improve the overall and disease-free survival of patients with breast cancer through efficient medicine.
引用
收藏
页数:11
相关论文
共 143 条
[51]   Comprehensive molecular portraits of human breast tumours [J].
Koboldt, Daniel C. ;
Fulton, Robert S. ;
McLellan, Michael D. ;
Schmidt, Heather ;
Kalicki-Veizer, Joelle ;
McMichael, Joshua F. ;
Fulton, Lucinda L. ;
Dooling, David J. ;
Ding, Li ;
Mardis, Elaine R. ;
Wilson, Richard K. ;
Ally, Adrian ;
Balasundaram, Miruna ;
Butterfield, Yaron S. N. ;
Carlsen, Rebecca ;
Carter, Candace ;
Chu, Andy ;
Chuah, Eric ;
Chun, Hye-Jung E. ;
Coope, Robin J. N. ;
Dhalla, Noreen ;
Guin, Ranabir ;
Hirst, Carrie ;
Hirst, Martin ;
Holt, Robert A. ;
Lee, Darlene ;
Li, Haiyan I. ;
Mayo, Michael ;
Moore, Richard A. ;
Mungall, Andrew J. ;
Pleasance, Erin ;
Robertson, A. Gordon ;
Schein, Jacqueline E. ;
Shafiei, Arash ;
Sipahimalani, Payal ;
Slobodan, Jared R. ;
Stoll, Dominik ;
Tam, Angela ;
Thiessen, Nina ;
Varhol, Richard J. ;
Wye, Natasja ;
Zeng, Thomas ;
Zhao, Yongjun ;
Birol, Inanc ;
Jones, Steven J. M. ;
Marra, Marco A. ;
Cherniack, Andrew D. ;
Saksena, Gordon ;
Onofrio, Robert C. ;
Pho, Nam H. .
NATURE, 2012, 490 (7418) :61-70
[52]  
Korkaya H., 2013, Nat Rev Cancer, V13, P763
[53]   A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer [J].
Koski, Gary K. ;
Koldovsky, Ursula ;
Xu, Shuwen ;
Mick, Rosemarie ;
Sharma, Anupama ;
Fitzpatrick, Elizabeth ;
Weinstein, Susan ;
Nisenbaum, Harvey ;
Levine, Bruce L. ;
Fox, Kevin ;
Zhang, Paul ;
Czerniecki, Brian J. .
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (01) :54-65
[54]  
Kouloulias VE, 2002, CLIN CANCER RES, V8, P374
[55]   Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives [J].
Krasniqi, E. ;
Barchiesi, G. ;
Pizzuti, L. ;
Mazzotta, M. ;
Venuti, A. ;
Maugeri-Sacca, M. ;
Sanguineti, G. ;
Massimiani, G. ;
Sergi, D. ;
Carpano, S. ;
Marchetti, P. ;
Tomao, S. ;
Gamucci, T. ;
De Maria, R. ;
Tomao, F. ;
Natoli, C. ;
Tinari, N. ;
Ciliberto, G. ;
Barba, M. ;
Vici, P. .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
[56]   Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good [J].
Krebs, Kristi ;
Milani, Lili .
HUMAN GENOMICS, 2019, 13 (01) :39
[57]   HER2 in Breast Cancer: A Review and Update [J].
Krishnamurti, Uma ;
Silverman, Jan F. .
ADVANCES IN ANATOMIC PATHOLOGY, 2014, 21 (02) :100-107
[58]   The breakthrough of the microbiota [J].
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (02) :87-+
[59]   Hydrophilic Acylated Surface Protein A (HASPA) of Leishmania donovani: Expression, Purification and Biophysico-Chemical Characterization [J].
Kumar, Manoj ;
Ranjan, Kishu ;
Singh, Vijay ;
Pathak, Chandramani ;
Pappachan, Anju ;
Singh, Desh Deepak .
PROTEIN JOURNAL, 2017, 36 (04) :343-351
[60]   Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer [J].
Kwa, Maryann ;
Li, Xiaochun ;
Novik, Yelena ;
Oratz, Ruth ;
Jhaveri, Komal ;
Wu, Jennifer ;
Gu, Ping ;
Meyers, Marleen ;
Muggia, Franco ;
Speyer, James ;
Iwano, Alyssa ;
Bonakdar, Maryam ;
Kozhaya, Lina ;
Tavukcuoglu, Ece ;
Budan, Bahar ;
Raad, Roy ;
Goldberg, Judith D. ;
Unutmaz, Derya ;
Adams, Sylvia .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) :57-67